# DSIP Research: The Studies, Measured and Cited > DSIP research, study by study: the 1977 EEG isolation, the 25 nmol/kg human sleep data, a ~35% rat delta-power increase, the HPA-axis findings, and a 2024 fusion-peptide result cutting wakefulness ~31%. Every quantitative finding mapped to its source — and every place the data runs out. ## Before the details Here is the whole DSIP research picture in plain words. The story starts in 1977 with one clean result: a nine-amino-acid peptide, pulled from sleeping rabbits, made deep-sleep brain waves stronger [1]. Over the next decades, animal studies repeated that EEG effect — rats showed roughly a 35% jump in slow-wave power [9], cats slept more deeply [10] — and a handful of small human studies in the 1980s reported better sleep [2][7]. Researchers also found DSIP doing other things in the body, like nudging stress hormones [4]. But the field never found the receptor it works through, never ran a large modern trial, and a 2006 review called the sleep evidence weak [3]. A 2024 study tried a re-engineered version and got a stronger result in mice [6]. The sections below walk through each of these, with the numbers. ## The 1977 isolation that named the peptide DSIP's entire identity traces to one experiment. Schoenenberger and Monnier isolated a nonapeptide — sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu — from the cerebral venous blood of rabbits whose brains had been put into an electrically induced sleep, and demonstrated that infusing it into the brain produced a significant and specific enhancement of delta and spindle EEG activity [1]. "Delta" refers to the slowest, highest-amplitude brain waves (roughly 0.5-4 Hz) that dominate deep, restorative sleep; "spindles" are the brief ~11-16 Hz bursts of stage-2 non-REM sleep. That the peptide amplified both is the founding observation the name encodes. ## The animal EEG and sleep data The clearest, most reproducible DSIP findings are in animals. In rats, DSIP produced about a 35% mean increase in neocortical and limbic delta EEG power, with more frequent theta bursts and effects sustained for up to 11 hours [9] — a large, durable shift in the exact brain-wave band the peptide is named for. In cats, a single 120 nmol/kg subcutaneous (under-the-skin) dose significantly increased slow-wave sleep, did not suppress REM, and reduced waking [10]. Because the dose was peripheral rather than injected into the brain, the result also speaks to delivery: DSIP appears to cross from the bloodstream into the central nervous system, consistent with the saturable, high-affinity blood-brain-barrier transport described elsewhere in the literature. ## The human sleep studies The human evidence is genuinely encouraging on its face but genuinely thin. In six middle-aged chronic insomniacs, a single intravenous dose of 25 nmol/kg lengthened sleep, reduced interruptions, slightly raised REM, and produced no daytime sedation — with the benefit emerging in the second hour after injection (and a slight arousal in the first hour) [2]. That second-hour onset is a recurring detail: DSIP's human effect, where present, is not instant. A separate report in severe chronic insomnia found improved sleep efficiency and duration alongside significant gains in daytime alertness and performance, with benefits carrying into the first post-treatment night [7]. DSIP was also used to correct phase-shifted insomnia, where one report described a roughly 5-hour advance of the sleep phase, complete withdrawal from a hypnotic, and a normalized sleep profile maintained at follow-up [8]. All of these are small, often single-center, and decades old — none has been reproduced in a modern controlled trial. ## The neuroendocrine and longevity findings DSIP's reach extends past sleep, which is part of why its biology is so unsettled. Intravenous DSIP at 25 nmol/kg in men reduced plasma ACTH-like immunoreactivity for at least three hours while cortisol followed its normal diurnal decline [4] — a selective touch on the HPA stress axis, though notably not reproduced in every later human study. In dissociated mouse pituitary cells, DSIP was co-localized with TSH in thyrotrophs and inhibited basal and CRF-induced ACTH release, while CRF and vasopressin in turn suppressed DSIP secretion by up to 63%, hinting at reciprocal HPA regulation [12]. DSIP-like immunoreactivity has also been mapped to gut endocrine cells across human, pig, and rat, with the human gut the richest source [13]. The most dramatic numbers come from aging research. Monthly courses of the DSIP-containing preparation Deltaran (~100 µg/kg, 5 days/month) in female SHR mice increased maximum lifespan by 24.1%, extended the last 10% of survivors' lifespan by 17.1%, cut spontaneous tumor incidence 2.6-fold, and reduced bone-marrow chromosome aberrations by 22.6% [5]. These are striking — but they come largely from a small set of related research groups and need independent replication before any strong claim. ## The 2024 fusion-peptide result The most recent advance is engineering, not native DSIP. In a 2024 study, a DSIP fusion peptide built to cross the blood-brain barrier (DSIP-CBBBP) reduced average daily wakefulness from about 720 to about 500 minutes — roughly 31% — in PCPA-induced insomnia mice, restored melatonin, serotonin, and dopamine, produced anxiolytic and antidepressant behavioral effects, and increased hippocampal neuron density, outperforming unmodified DSIP [6]. This fits the 2006 review's key observation: structural analogs, not the native peptide, tend to drive the clearest effects [3]. ## How to read the DSIP evidence The most important interpretive fact is the absence of a mechanism. Despite four decades of work, no DSIP gene, precursor protein, or specific receptor has been conclusively identified, and a 2006 Journal of Neurochemistry review called the sleep-promotion hypothesis "extremely poorly documented and still weak," noting that brain distribution sits in regions not clearly relevant to sleep regulation [3]. Cross-species results diverge — rat GH effects did not reproduce in human women, and an early human ACTH-lowering finding [4] was not confirmed in later HPA work. DSIP also shows a parabolic dose-response, where intermediate doses can outperform higher ones, complicating any dose interpretation [11]. The result is a compound with a real, named EEG signature, scattered intriguing findings, and no validated human pharmacology — exactly the state a careful reader should hold in mind. --- A data-forward digest of the delta sleep-inducing peptide literature — every figure sourced, every gap named, and no clinic, vendor, or prescription behind the numbers.